All regulations
Nonrulemaking
FDA
Open for Comments
FDA-2026-P-4060
Request that the FDA declare that an ANDA may be submitted for, Haloperidol Tablets USP, 0.25 and 2.5 mg, two strengths that differ from the currently approved RLD, HALDOL (Haloperidol) tablets from ORTHO MCNEIL PHARMACEUTICAL, which FDA approved in 0.5 mg, 1 mg, 2 mg, 5 mg, 10 mg, and 20 mg strengths prior to Jan 1, 1982 under NDA #015921
Documents
7
Comments
0
Description
OPEN
Key Dates
Comment Period OpensApr 14, 2026
Documents
| Type | Title | Status |
|---|---|---|
Other |
Keywords
CDER
Suitability Petition
Appco Pharma, LLC
declare that an ANDA may be submitted for
Haloperidol Tablets USP, 0.25 and 2.5 mg,
Jan 1, 1982 under NDA #015921
two strengths that differ from the currently
approved RLD, HALDOL (Haloperidol) tablets
Data from Regulations.gov